Neurocrine initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Neurocrine with an Outperform rating and a price targets of $113. The analyst cites his above-consensus estimates for Ingrezza at $1.76B, the multiple opportunities for long term upside to penetration rates, and its pipeline that is not being fully appreciated.
https://thefly.com/landingPageNews.php?id=2891647
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.